1. Articles in category: Pharma

    1-17 of 17
    1. EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

      EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

      HEMEL HEMPSTEAD, England and VIENNA, March 27, 2017 /PRNewswire/ -- EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today announced that the European Medicines Agency's (EMA) Committee for Medicinal...

      Read Full Article
      Mentions: Treatment
    2. Childhood cancer in small geographical areas and proximity to air-polluting industries.

      Childhood cancer in small geographical areas and proximity to air-polluting industries.

      Environ Res. 2017 Mar 16;156:63-73

      Authors: Ortega-García JA, López-Hernández FA, Cárceles-Álvarez A, Fuster-Soler JL, Sotomayor DI, Ramis R

      Abstract AIM: Pediatric cancer has been associated with exposure to certain environmental carcinogens. The purpose of this work is to analyse the relationship between environmental pollution and pediatric cancer risk.

      Read Full Article
    3. Stand Up To Cancer Launches "Catalyst," a New Research Program Supported by Industry

      "Under the SU2C Catalyst program, companies like Merck, Bristol-Myers Squibb and Genentech will donate funds to support collaborative research studies using products the companies will provide, such as new pharmaceutical compounds that they are developing or approved agents that can be investigated for other uses.  

      Through its scientific partner, the American Association for Cancer Research (AACR), SU2C will issue a Request for Proposals (RFP) to the scientific community based on each company's commitment of funding and materials such as drugs and diagnostic tests. The RFP will lay out the compounds that will be available, the research emphasis, the estimated ...

      Read Full Article
    4. Children's clinical cancer trials: what needs to change to allow children access to new cancer drugs?

      Children's clinical cancer trials: what needs to change to allow children access to new cancer drugs?

      Expert Rev Clin Pharmacol. 2015 Aug 26;:1-3

      Authors: Moreno L, Pearson AD

      Abstract Despite numerous advances with the incorporation of multimodal treatment, children with cancers have a major unmet need to access new drugs. Still, a reduced number of new targeted drugs is evaluated in pediatric patients and very few of them progress into late phase trials and clinical use.

      Read Full Article
    5. O3.3Covalent CDK-7 inhibitors as new anti-cancer agents.

      From Pharma: "Interestingly, we find CDK7 to be associated with a class of recently described transcriptional regulatory elements termed 'super-enhancers', and show that these compounds specifically antagonize super-enhancer driven gene expression to selectively revert oncogenic transcriptional programs in multiple disease models.These compounds are well tolerated in mice and we have developed an assay to show target engagement in vivo. Testing these compounds in multiple mouse models of human cancer (CDX, PDX and GEMM) we see in vivo efficacy in T-ALL, neuroblastoma and SCLC (including regressions). We describe specific examples of the impact of CDK7 inhibition on the oncogenic transcription ...

      Read Full Article
    6. FDA approves Unituxin for pediatric patients with high-risk neuroblastoma

      FDA approves Unituxin for pediatric patients with high-risk neuroblastoma

      The FDA today announced the approval of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, according to a press release from the drug’s manufacturer. Dinutuximab (Unituxin, United Therapeutics) is an antibody designed to bond to the surface of neuroblastoma cells and is approved as part of a multimodality regimen, including surgery, chemotherapy and radiation therapy for pediatric patients who achieved at least a partial response to prior first-line multi-agent, multimodality therapy.

      Read Full Article
    7. Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil™)

      Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil™)

      "Apotex is the only company to date to have two biosimilar filgrastim applications (pegfilgrastim and filgrastim) currently under active review by FDA. Filgrastim is used to help cancer patients taking chemotherapies fight infections and fever by boosting white blood cell counts.  According to Symphony Health Solutions, Neupogen had approximately $1-billion in sales in calendar year 2014."

      Read Full Article
    8. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma

      NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma

      LAGUNA HILLS, Calif., Feb. 11, 2015 /PRNewswire/ -- NanoSmart® Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration (FDA) for one of its lead candidates,...

      Read Full Article
    9. Abcam Licenses Novel Ceefourin Inhibitors of Multidrug Resistance Protein 4 from Children’s Cancer Institute

      Abcam Licenses Novel Ceefourin Inhibitors of Multidrug Resistance Protein 4 from Children’s Cancer Institute

      19 Sep 2014

      Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development

      Sydney, Australia and Cambridge, UK, 19 September, 2014: Children’s Cancer Institute and Abcam plc, a global leader in the supply of innovative protein research tools and services, announced today that they have entered into an exclusive licence, supply and distribution agreement for multidrug resistance protein 4 (MRP4/ABCC4) inhibitors, Ceefourin™ 1 and Ceefourin™ 2, for research purposes.

      The first known selective inhibitors of MRP4, Ceefourin™ 1 and Ceefourin™ 2 are potent, chemically distinct compounds and are the first known selective inhibitors of ...

      Read Full Article
    10. Ignyta Announces Initiation of STARTRK-1 Global Phase I/II Clinical Trial of RXDX-101

      Ignyta Announces Initiation of STARTRK-1 Global Phase I/II Clinical Trial of RXDX-101
      SAN DIEGO--(BUSINESS WIRE)--July 21, 2014-- 

      Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced the multicenter initiation of the company's global Phase I/II clinical trial of RXDX-101, its proprietary oral tyrosine kinase inhibitor targeting multiple solid tumor indications. This clinical trial is called STARTRK-1, which stands for Study Targeting ALK, ROS1 or TRKA/B/C, and is a Phase I/IIa, multicenter, single-arm, open-label clinical trial of continuous daily dosing of oral RXDX-101 in adult patients with locally advanced or metastatic cancer confirmed to be positive for relevant molecular alterations.

      Read Full Article
      Mentions: ALK ASCO
    11. Austrian Biotech Company “APEIRON” Announces Start of its First Clinical Trial for Neuroblastoma Patients in Japan

      Austrian Biotech Company “APEIRON” Announces Start of its First Clinical Trial for Neuroblastoma Patients in Japan

      Japan a New Hotspot for International Pharma and Biotech Research?

      Tokyo, Vienna, July 7th, 2014: Austrian biotech company APEIRON Biologics AG (“Apeiron”) announced today that a phase I clinical trial with its neuroblastoma immunotherapy APN311 has received all necessary approvals to start recruiting patients. The trial will be locally conducted by Nagoya University Hospital and is part of a long-term collaboration to make this therapy available to patients suffering from this severe type of children’s cancer. In Japan, it won a grant by ...

      Read Full Article
    1-17 of 17
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. General Informations in the News

    1. (1 articles) Treatment